Savara Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Savara Inc. on March 10, 2021, covering events occurring between March 5, 2021, and March 10, 2021. The Company is a Delaware corporation focused on developing molgramostim for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP).
Key Financial Metrics and Agreements
This filing does not contain audited financial statements, revenue, profit, or cash flow data. However, it discloses significant contractual commitments:
- Master Services Agreement: Entered into on March 5, 2021 (effective January 6, 2021) with Parexel International (IRL) Limited for contract research services.
- Work Order #1: Executed contemporaneously for the IMPALA 2 Phase 3 clinical trial. The estimated aggregate cost for service fees and pass-through expenses is approximately $31 million.
- Executive Compensation: A new employment agreement with Chief Medical Officer Dr. Badrul Chowdhury provides an annual base salary of $540,750 and a performance-based bonus of up to 40% of base salary.
Material Changes and Operational Updates
The primary material change is the formalization of the partnership with Parexel to manage the IMPALA 2 trial. Additionally, the Company disclosed operational details regarding the trial:
- Trial Scope: The IMPALA 2 trial is a Phase 3, 48-week, randomized, double-blind, placebo-controlled study.
- Enrollment: The trial will be conducted at approximately 50 sites and is expected to fully enroll in approximately 20 months following initiation.
- Supply Chain: The Company is pursuing a second source manufacturer for molgramostim to ensure drug substance supply and mitigate approvability risk.
Guidance, Outlook, and Risks
Management provided the following outlook and risk factors:
- Data Timeline: Top-line data from the IMPALA 2 trial are anticipated in the second quarter of 2024.
- Pandemic Risk: The Company noted that the evolving impact of the COVID-19 pandemic may adversely affect trial timelines, despite mitigation strategies.
- Termination Rights: The agreement with Parexel allows for termination without cause on 60 days' prior written notice, or immediately for material breaches, insolvency, or regulatory revocations.
Key Facts for Investor Verification
- Verify the total cash burn rate and current liquidity position to assess the ability to fund the $31 million estimated cost for the IMPALA 2 trial.
- Monitor the progress of securing a second source manufacturer for molgramostim to mitigate supply chain risks.
- Track enrollment rates at the 50 planned sites to confirm the 20-month full enrollment timeline.
- Review the specific performance objectives for the CMO's bonus to understand potential future cash outflows.
- Confirm the filing of the full text of the Master Services Agreement and Work Order in the upcoming Form 10-Q for the quarter ended March 31, 2021.